ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Appendix D: Search Strategy for Literature Addressing HCV Prevalence,* by Database
|
Database† |
Search terms |
No. hits |
No. with abstracts |
|---|---|---|---|
|
Cochrane Database |
1. (Hepatitis C OR Hep C OR HCV) t.ti,ab,kw |
Cochrane reviews:32 |
1,648 |
|
Economic evaluations:223 |
|||
|
2. Hepatitis C.kw |
Clinical trials:1,720 |
||
|
CINAHL |
1. (MM "Hepatitis C+") |
3,236 |
647 |
|
2. (MH "Hepatitis C+") |
4,503 |
||
|
3. (MH "Antibodies+") |
16,891 |
||
|
4. (MH "Antibodies +") and (S2 and S3) |
304 |
||
|
5. TX prevalence OR frequen* |
115,230 |
||
|
6. Cohort* or cross-section* or cross section* |
78,023 |
||
|
7. (MH "Epidemiological Research+"# OR #MH "Epidemiology+"#) |
217,794 |
||
|
8. (MH "Environment and Public Health (Non-Cinahl)") |
6,696 |
||
|
9. 1 OR 4 |
3,298 |
||
|
10. 5 OR 6 OR 7 OR 8 |
339,418 |
||
|
11. (5 OR 6 OR 7 OR 8) and (9 and 10) |
793 |
||
|
MEDLINE |
1. Hepatitis C [majr] OR Hepatitis C Antibodies [majr] |
22,809 |
6,159 |
|
2. 1 AND (Prevalence OR frequen*) |
9,134 |
||
|
3. 2 AND (Cohort or cross-sectional OR "cross-sectional" or Epidemiologic Studies [mesh]) |
4,005 |
||
|
EMBASE |
1. *Hepatitis C/ or *Hepatitis C Antibody/ |
35,963 |
6,159 |
|
2. (prevalence OR frequen*).mp |
890,278 |
||
|
3. (cohort OR cross-sectional or "cross adj sectional").mp |
346,055 |
||
|
4. *epidemiology/ |
10,345 |
||
|
5. 1 AND (2 OR 3 OR 4) |
6,835 |
||
|
Sociological Abstracts |
1. Hep C OR hepc or hepatitis C (ti, kw, au, de) |
—§ |
160¶ |
|
2. HCV (ti) |
— |
||
|
3. 1 OR 2 |
— |
||
|
Database of Abstracts of Reviews of Effects |
1. Explode Hepatitis C |
279 |
171 |
|
2. Explode Hepatitis C Antibodies |
11 |
||
|
3. Explode Hepatitis C, Chronic |
144 |
||
|
4. 1 OR 2 OR 3 |
280 |
||
|
Abbreviations: HCV = hepatitis C virus. * The HCV-prevalence literature search was conducted to determine the effect of a birth-year based testing strategy versus the standard of care (i.e., risk-based testing) for identification of HCV infection. † Search was conducted for literature published during 1995–2011. § Unavailable. ¶ Of these hits, 159 were de-duplicated (i.e., remained after duplicate study reports were identified). |
|||
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
